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baseline of 66 μg/mL, and clobazam 367 ng/mL (normal range
30–300 ng/mL).
Conclusion: Cannabidiol contained in hemp oil extract inhibits
CYP3A4 and CYP2C19, the primary isoenzymes involved in the
metabolism of clobazam, and inhibits UDP-glucuronyl transferase,
which is involved in the metabolism of lamotrigine and valproic
acid. Symptomatic elevations in valproic acid and clobazam have
been reported following the addition of cannabidiol to antiepi-
leptic therapeutic regimens. Several studies have reported the
efficacy of cannabidiol as an adjuvant therapy for refractory epi-
lepsy, however evidence suggests that hemp extract may cause
elevations of serum concentrations of various AEDs. Clinicians
should be aware that the use of hemp extract in combination
with AEDs requires caution and careful monitoring of serum AED
concentrations.
219. Paracetamol-induced renal
failure: an underestimated
consequence of delayed managed
overdoses
Bastien Domangé, Corinne Schmitt, Romain Torrents,
Audrey Boulamery, Nicolas Simon and Luc De Haro
Marseille Poison Centre, Marseille, France
Objective: Paracetamol poisoning is one of the most frequent
drug intoxications with well-known risk of liver toxicity. However
the direct renal toxicity of this painkiller is still mysterious and
much less studied. In Southern France, paracetamol overdose is
an everyday problem but observations with proven renal damage
seem to be rare. In order to illustrate this notion, 9 cases of renal
failure during paracetamol overdose managed in the Marseille
Poison Centre are detailed.
Case series: Nine cases (6 suicide attempts, 3 self-medications)
were studied, concerning 6 women and 3 men between 13 to 70
years old. In 7 cases there was acute poisoning after a massive
quantity of paracetamol and 2 cases involved repeated high
doses over 3 to 5 days. A classic hepatic cytolysis was observed
in 7 cases but for 2 patients there was no liver impact. The acute
kidney injury scores (Acute Kidney Impairment Network) were
two grade I, two grade II and five grade III. Hemodialysis was
required for 4 patients with grade III kidney impairment; all of
them had delayed medical management. Oliguria/anuria was pre-
sent for 3 to 14 days. For 2 patients a kidney biopsy was per-
formed and showed a toxic acute tubular necrosis. All patients
recovered.
Conclusion: Direct paracetamol toxicity on the kidneys seems to
be a rare but serious event. This kind of toxicity is only reported
when an oliguria or anuria is present; however in our everyday
practice we do not evaluate the renal impact during a common
paracetamol overdose. The kidney toxicity of paracetamol is cer-
tainly underestimated and should be studied more seriously. An
important recent study [1] examined the correlation between the
severity of the hepatic failure and the development of kidney dis-
turbances, the possible efficient therapeutic activity of the acetyl-
cysteine on the renal toxicity of the paracetamol, and the higher
risk of renal failure when the medical management is delayed.
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Objective: Paracetamol (acetaminophen) overdose is the most
common cause of liver toxicity in the Western world but patient
stratification is sub-optimal. A number of new biomarkers that
have improved hepatic expression (miR-122) or provide mechan-
istic insights (keratin-18 [K18], High Mobility Group Box-1
[HMGB1]), have been proposed to have higher specificity and
sensitivity than currently used tests. The objective of this study
was to prospectively explore the ability of these biomarkers to
stratify patients by risk of subsequent liver injury in 2 paraceta-
mol overdose patient cohorts that faithfully represented the spec-
trum of clinical presentations requiring treatment with
acetylcysteine.
Methods: Patients who needed acetylcysteine treatment for para-
cetamol overdose were recruited. Independent derivation
(Markers and Paracetamol Poisoning, 8 UK hospitals) and valid-
ation (Biomarkers of Paracetamol Hepatotoxicity, 10 UK hospitals)
studies prospectively recruited 985 and 202 patients, respectively.
Circulating biomarkers were measured at hospital presentation.
The primary endpoint was acute liver injury (ALI), defined as peak
alanine transaminase activity (ALT)>100 U/L. Secondary end-
points included ALT >1000 U/L and liver synthetic dysfunction
(INR >1.5). Receiver Operator Characteristic Area Under the Curve
(ROC-AUC) and Multivariate Net Reclassification Index (NRI) analy-
ses were utilised to determine the ability of these novel bio-
markers to stratify patients by liver injury risk.
Results: In the derivation and validation cohorts, ALI was pre-
dicted at presentation to hospital with high sensitivity and speci-
ficity by miR-122, HMGB1 and full length-K18 (FL-K18) (ROC-AUC
values: 0.97 [0.95–0.98], 0.95 [0.93–0.98] and 0.95 [0.92–0.97],
respectively). High predictive accuracy was maintained when the
cohorts were censored by normal presentation ALT, time from
overdose and overdose type (acute or staggered). For prediction
of INR elevation, HMGB1 had the maximal prognostic ability in
acute and staggered overdoses in both the derivation and valid-
ation cohorts (ROC-AUC: 0.94 [0.88–1.00]) compared with ALT
(0.55 [0.39–0.72]).
Conclusion: In these two multi-centre prospective studies, we
have demonstrated that a panel of mechanistic circulating bio-
markers can predict subsequent liver injury and dysfunction
with high accuracy despite treatment with acetylcysteine. Using
these biomarkers, a precision medicine approach to patient
stratification and management can be applied at hospital pres-
entation. This study has directly contributed to the regulatory
(Food and Drug Administration [FDA] and European Medicines
Agency [EMEA]) letters of support for the further qualification of
these biomarkers across the spectrum of drug-induced liver
injury.
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